A phase II study of UFT and leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer

Gyldenkerne, Niels; Glimelius, Bengt; Frödin, Jan Erik; Kjær, Mogens; Pfeiffer, Per; Hansen, Finn Thorbjørn; Keldsen, Nina; Sandberg, Erik; Jakobsen, Anders

doi:10.1080/02841860410028655

Cited by 7 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mitomycin C is used in the treatment of bladder, colorectal, gastric, and lung cancers [117][118][119]. Mitomycin was used in combination with Leucovorin and Fluorouracil to treat advanced colon cancer [85]. The lognormal parameters from the survival curve were compared to other treatments of colon cancer ( Table 3) .…”

Section: Cetuximabmentioning

confidence: 99%

“…Capecitibine, floxuridine, gemcitibine, and tegafur have been developed as prodrugs of 5-fluorouracil [27]. Flourouracil was used in 4 arms of the pancreatic cancer (Table 1; [53,61,78]) and 11 arms of colon cancer ( Table 3; [79][80][81][82][83][84][85]) survival curves used for meta analyses. .…”

Section: Cetuximabmentioning

confidence: 99%

“…Levo-folinic acid is just the L form of the acid, while folinic acid and leucovorin are racemic mixtures of the D and L forms. Folinic acid was used in 11 arms of the colon cancer studies ( Table 3; [79][80][81][82][83][84][85]). .…”

Section: Cetuximabmentioning

confidence: 99%

See 2 more Smart Citations

Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols

Qazi

DuMez²,

Uckun³

2007

CPD

View full text Add to dashboard Cite

We describe the use of a parametric lognormal model to calculate and compare survival statistics in the clinical treatment of advanced/metastatic pancreatic, breast and colon cancers. The fit using the lognormal model explained greater than 90% (R(2) ranged from 0.917 to 0.998 for a total of the 51 arms from published studies) of the variation in the cumulative survival statistics of patients treated for advanced cancers. A meta-analytic Q-test was performed to test whether there were significant differences between different studies. For all three cancer types, the Q-test showed highly significant differences between the survival arms (p<0.0001 for pancreatic, breast and colon cancers). The z-values expressed the difference of the average of lognormal means relative to each study in terms of deviation expressed in standard errors. The treatments that were most effective ranked with the highest z-value: Doxorubicin plus docetaxel for pancreatic cancer (z-value = 4.1); Capecitabine plus paclitaxel for breast cancer (z-value = 3); irinotecan, fluorouracil and folinate for colon cancer (z-value = 7.4).

show abstract

Section: Cetuximabmentioning

confidence: 99%

Section: Cetuximabmentioning

confidence: 99%

See 1 more Smart Citation

Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols

Qazi

DuMez²,

Uckun³

2007

CPD

View full text Add to dashboard Cite

show abstract

“…Concurrent with radiation cohorts of three patients received increasing doses of oral UFT (150 to 300 mg/m 2 /day, five days a week for 30 days), divided in three doses plus a fixed dose of Isovorin 7.5 mg [19,20] with each UFT dose (Table I). Sufficient serum and tumour concentrations can be obtained by this schedule [18].…”

Section: Chemotherapymentioning

confidence: 99%

High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: A phase I trial

Pfeiffer

2005

Acta Oncologica

Self Cite

View full text Add to dashboard Cite

A phase I trial of preoperative high dose pelvic radiotherapy and oral UFT/l-leucovorin in patients with locally advanced and unresectable rectal cancer patients to evaluate toxicity and efficacy was performed. Eighteen patients (14 with primary unresectable tumours and four with locally recurrent tumours) were treated. All patients were evaluable for acute toxicity and efficacy. Patients received increasing doses of UFT (150 to 300 mg/m2/day UFT and a fixed dose of 22.5 mg/day l-leucovorin) with each fraction, five days a week for 30 days, concomitantly with pelvic radiotherapy (60 Gy in 30 fractions using concomitant boost technique). All patients received the planned dose of radiotherapy. No hematological toxicity was observed. Only one patient developed grade 3 toxicity (diarrhea). Fourteen patients (78%) had surgery (11 R0 and 3 R1) after median 40 days. Two patients (11%) had a complete pathological response. Ten patients are alive after median follow-up of 49 months. Toxicity, resection rate and survival are very encouraging and the study continues as a phase II trial.

show abstract

MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression

et al. 2017

View full text Add to dashboard Cite

show abstract

A phase II study of UFT and leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer

Cited by 7 publications

References 10 publications

Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols

Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols

High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: A phase I trial

MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression

Contact Info

Product

Resources

About